Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2007, Pages 935-942

  Scaglione, G ^a,b   Pietrini, L ^a   Russo, F ^a   Franco, M R ^a   Sorrentini, I ^a  

^a A O G Rummo   (Italy)

^b G RUMMO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; LONG ACTING DRUG; OCTREOTIDE;

ADULT; AGED; ANGIODYSPLASIA; ARTICLE; BLOOD TRANSFUSION; CAPSULE ENDOSCOPY; CLINICAL ARTICLE; DIARRHEA; DRUG FORMULATION; DRUG SAFETY; FEMALE; FOLLOW UP; GALLSTONE; GASTROINTESTINAL ANGIODYSPLASIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; IRON THERAPY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANGIODYSPLASIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; OCTREOTIDE; PEPTIC ULCER HEMORRHAGE; TIME; TREATMENT OUTCOME;

EID: 34548305003     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03435.x     Document Type: Article

References (35)

1. Foutch PG. Angiodysplasia of the gastrointestinal tract. Am J Gastroenterol 1993 88 : 807 18.
2. Blair SL. Small intestinal bleeding. Gastroenterol Clin North Am 1994 23 : 67 91.
3. Richter JM. Occult gastrointestinal bleeding. Gastroenterol Clin North Am 1994 23 : 53 65.
4. Zuckerman GR, Prakash C, Askin MP, Lewis BS. Technical review: the evaluation and management of occult and obscure GI bleeding. Gastroenterology 2000 118 : 201 21.
5. Van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990 335 : 953 5.
6. Di Girolamo G, Malavasi A, Cassisa L, Cossu ML, Dettori G, Realdi G. Chronic bleeding caused by small bowel angiodysplasia: a problem of recognition and diagnosis. Ital J Gastroenterol 1992 24 : 468 9.
7. Sharma R, Gorbien MJ. Angiodysplasia and lower gastrointestinal tract bleeding in elderly patients. Arch Intern Med 1995 155 : 807 12.
8. Williams CN. Angiodysplasia of the gastrointestinal tract. Can J Gastroenterol 1997 11 : 123.
9. Marshall JK, Hunt RH. Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities. Eur J Gastroenterol Hepatol 1997 9 : 521 5.
10. Brown SG, Swain CP, Storey DW, et al. Endoscopic laser treatment of vascular anomalies of the upper gastrointestinal tract. Gut 1985 26 : 1338 48.
11. Gostout CJ, Bowyer BA, Ahiquist DA, Viggiano TR, Balm RK. Mucosal vascular malformations of the gastrointestinal tract: clinical observations and results of endoscopic neodymium: ytrium-aluminum-Garnet laser therapy. Mayo Clin Proc 1988 63 : 993 1003.
12. Lewis BS, Salomon P, Rivera-MacMurray S, Kornbluth AA, Wenger J, Waye J. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol 1992 15 : 99 103.
13. Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001 121 : 1073 9.
14. Lamberts S, van der Lely AJ, de Herder WW, Hofland JL. Octreotide. N Engl J Med 1996 25 : 246 54.
15. Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999 11 : 1429 36.
16. Junquera F, Saperas E, Videla S, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol 2007 102 : 254 60.
17. Orsi P, Guatti-Zuliani C, Okolicsanyi L. Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract. Dig Liver Dis 2001 33 : 330 4.
18. Howard OM, Buchanan JD, Hunt RH. Angiodysplasia of the colon. Experience of 26 cases. Lancet 1982 2 : 16 19.
19. Richter JM, Christensen MR, Colditz GA, Nishioka NS. Angiodysplasia: natural history and efficacy of therapeutic interventions. Dig Dis Sci 1989 34 : 1542 6.
20. Barkin JS, Ross BS. Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol 1998 93 : 1250 4.
21. Anthony LB. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 1999 31 (Suppl. 2 S216 8.
22. Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989 110 : 35 50.
23. McKeage K, Cheer S, Waqstaff AJ. Octreotide long-acting release (LAR). A review of its use in the management of acromegaly. Drugs 2003 63 : 2473 99.
24. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006 64 : 342 51.
25. Arnold M, Wied M, Behr TH. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002 3 : 643 56.
26. Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006 13 : 1213 21.
27. Becker G, Allgaier HP, Olschewki M, Zahringer A, Blum HE. HECTOR study group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007 45 : 9 15.
28. Reynaert H, Geerts A. Review article: pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 2003 18 : 375 86.
29. Chowers Y, Cahalon L, Lahav M, et al. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol 2000 165 : 2955 61.
30. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004 102 : 61 85.
31. Hogenauer C, Aichbichler B, Santa Ana C, Porter J, Fortran J. Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo. Aliment Pharmacol Ther 2002 16 : 769 77.
32. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995 16 : 86 88.
33. Gugger M, Waser B, Kappeler A, Schonbrunn A, Reubi JC. Cellular detection of sst2A receptors in human gastrointestinal tissue. Gut 2004 53 : 1431 6.
34. Witzig TE, Kvols LK, Moutel CG, Bowie EJ. Effect of the somatostatin analogue octreotide acetate on hemostatis in humans. Mayo Clin Proc 1991 66 : 283 6.
35. Zuckerman GR, Cornette GL, Clouse RE, Harter HR. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 1985 102 : 588 92.